Taro gets FDA approval for generic version of Lamisil
-
- July
- 3
Taro Pharmaceutical Industries Ltd., a generic-drug maker with operations in Hawthorne, has received final approval from the U.S. Food and Drug Administratio for for Terbinafine Hydrochloride Cream 1%. Taro’s terbinafine cream is a generic version of Lamisil Cream from Novartis Consumer Health Inc. Terbinafine cream is sold over-the-counter to treat fungal ailments, such as athlete’s foot, jock itch and ringworm. It relieves the itching, cracking, burning and scaling that often is associated with these conditions. Citing industry sources, Taro said Lamisil Cream has annual U.S. sales of more than $50 million. In May, Taro Pharmaceutical Industries said it would be purchased by Sun Pharmaceutical Industries Ltd. of India for $454 million.









